BDR Pharmaceuticals International Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: BDR Pharmaceuticals International Private Limited Pharmaceutical Export Portfolio Dataset — 12 Products, $4.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

BDR Pharmaceuticals International Private Limited — Pharmaceutical Exporter Profile (2026) | 12 Products, $4.4M Trade | TransData Nexus

BDR Pharmaceuticals International Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $4.4M Total Trade · DGFT Verified

BDR Pharmaceuticals International Private Limited is an Indian pharmaceutical exporter with a total trade value of $4.4M across 12 products in 3 therapeutic categories. Based on 183 verified export shipments from Indian Customs (DGFT) records, BDR Pharmaceuticals International Private Limited is the #1 Indian exporter in 2 products including Thalidomide, Olaparib. Top exports include Tamoxifen ($830.4K), Everolimus ($750.0K), Lapatinib ($600.0K).

BDR Pharmaceuticals International Private Limited — Export Portfolio & Destination Treemap

BDR Pharmaceuticals International Private Limited pharmaceutical export portfolio — 12 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is BDR Pharmaceuticals International Private Limited? — Company Overview & Market Position

BDR Pharmaceuticals International Private Limited, established on September 24, 2002, is a privately held Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24230MH2002PTC137329. As of the latest available data, BDR Pharmaceuticals has an authorized capital of ₹1.12 crore and a paid-up capital of ₹53.99 lakh. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, focusing on therapeutic areas such as oncology, critical care, gynecology, and neurology.

What Does BDR Pharmaceuticals International Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tamoxifen$830.4K 2Everolimus$750.0K

Product Portfolio — Top 12 by Export Value

BDR Pharmaceuticals International Private Limited exports 12 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tamoxifen	Advanced Oncology	$830.4K	48	5.6%	4
2	Everolimus	Immunosuppressants	$750.0K	15	2.0%	4
3	Lapatinib	Advanced Oncology	$600.0K	12	11.2%	2
4	Capecitabine	Advanced Oncology	$599.5K	17	0.7%	13
5	Thalidomide	Advanced Oncology	$468.6K	23	24.2%	1
6	Amphotericin	Antifungals	$300.0K	6	0.3%	7
7	Olaparib	Advanced Oncology	$285.6K	15	31.0%	1
8	Sunitinib	Advanced Oncology	$198.2K	17	0.3%	8
9	Cabazitaxel	Advanced Oncology	$150.0K	3	1.6%	6
10	Lenvatinib	Advanced Oncology	$98.6K	21	4.6%	4
11	Pazopanib	Advanced Oncology	$92.0K	3	1.1%	5
12	Pomalidomide	Advanced Oncology	$19.4K	3	0.4%	7

BDR Pharmaceuticals International Private Limited exports 12 pharmaceutical products across 3 therapeutic categories with a total export value of $4.4M. The company is the #1 Indian exporter in 2 products: Thalidomide, Olaparib. The top category is Advanced Oncology (76.1% of portfolio), followed by Immunosuppressants (17.1%), indicating a concentrated portfolio with the top 5 products accounting for 74.0% of total export value.

BDR Pharmaceuticals International Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

BDR Pharmaceuticals operates state-of-the-art manufacturing facilities in Gujarat, India. The Vadodara unit specializes in oncology oral formulations and complies with WHO GMP and EU GMP standards. Additionally, the company has plans to establish a facility in Halol District, Gujarat, dedicated to oncological injectable dosage forms, targeting approvals from various international accreditation agencies.

3Key Leadership

Mr. Dharmesh Mahendra Shah serves as the Chairman and Managing Director of BDR Pharmaceuticals. A Chemical Engineer by training, Mr. Shah has over three decades of experience in the pharmaceutical industry, having previously held significant positions at Khojchem Pvt. Ltd. and Hetero Drugs Ltd. Under his leadership, BDR Pharmaceuticals has focused on the development and introduction of new molecules in critical therapeutic segments.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does BDR Pharmaceuticals International Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

BDR Pharmaceuticals has made significant strides in obtaining regulatory approvals for its products in various international markets. The Vadodara manufacturing unit's compliance with WHO GMP and EU GMP standards positions the company favorably for market access in the European Union. The planned facility in Halol District aims to secure approvals from multiple international accreditation agencies, including those in the United States, Europe, Africa, and Asia, thereby enhancing the company's global footprint.

2Emerging Markets

BDR Pharmaceuticals has strategically positioned itself to penetrate emerging markets in Africa, Latin America, and Southeast Asia. The company's focus on obtaining WHO prequalification for its products is a key enabler for accessing these markets, ensuring compliance with international quality standards and facilitating smoother entry into these regions.

3Geographic Strategy

BDR Pharmaceuticals' geographic strategy emphasizes diversification across various international markets, including the US, EU, UK, Australia, Japan, Africa, Latin America, and Southeast Asia. This approach mitigates concentration risk and aligns with the company's strategic direction to expand its global presence and reduce dependency on any single market.

BDR Pharmaceuticals International Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, specific details regarding BDR Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's focus on obtaining international accreditations, such as WHO GMP and EU GMP, suggests a commitment to meeting global regulatory standards, which may facilitate future FDA approvals.

2WHO & EU GMP

BDR Pharmaceuticals' Vadodara manufacturing unit complies with WHO GMP and EU GMP standards, reflecting the company's commitment to maintaining high-quality manufacturing practices. These certifications are crucial for accessing regulated markets and demonstrate adherence to international quality benchmarks.

3CDSCO & Indian Regulatory

BDR Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory authority. The company's facilities are approved by state drug controllers, and it possesses export No Objection Certificates (NOCs), enabling the export of pharmaceutical products to various international markets.

BDR Pharmaceuticals International Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology therapeutic segment, BDR Pharmaceuticals faces competition from established players such as Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries. The company's focus on niche products, including Tamoxifen, Everolimus, Lapatinib, Capecitabine, and Thalidomide, positions it as a specialized competitor in these areas. The company's market share in these products indicates a competitive presence, particularly in the Thalidomide segment, where it holds a 24.2% market share.

2Key Differentiators

BDR Pharmaceuticals' key differentiators include its focus on niche therapeutic segments, such as oncology, critical care, gynecology, and neurology, and its commitment to early identification and development of new molecules. The company's adherence to international quality standards, as demonstrated by its WHO GMP and EU GMP certifications, further distinguishes it in the competitive landscape.

3Strategic Position

BDR Pharmaceuticals' current strategic direction emphasizes the development and marketing of generic formulations, with a particular focus on oncology and critical care segments. The company's future outlook includes expanding its global presence through obtaining international accreditations and entering emerging markets, thereby enhancing its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating BDR Pharmaceuticals International Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

BDR Pharmaceuticals has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $4.4 million USD and 183 shipments across 12 products in 2022-2026. The company's portfolio concentration, with the top five products accounting for 74% of exports, indicates a focused approach to product development and market penetration. The company's adherence to international quality standards, as evidenced by its WHO GMP and EU GMP certifications, underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm the FDA approval status of specific products by checking the FDA's Orange Book or contacting the FDA directly.

WHO-GMP Certification: Verify the WHO-GMP certification by consulting the World Health Organization's official website or contacting the organization.

Frequently Asked Questions — BDR Pharmaceuticals International Private Limited

How many pharmaceutical products does BDR Pharmaceuticals International Private Limited export from India?

BDR Pharmaceuticals International Private Limited exports 12 pharmaceutical products across 3 therapeutic categories. The top exports are Tamoxifen ($830.4K), Everolimus ($750.0K), Lapatinib ($600.0K), Capecitabine ($599.5K), Thalidomide ($468.6K). Total export value is $4.4M.

What is BDR Pharmaceuticals International Private Limited's total pharmaceutical export value?

BDR Pharmaceuticals International Private Limited's total pharmaceutical export value is $4.4M, based on 183 verified shipments recorded in Indian Customs (DGFT) data.

In which products is BDR Pharmaceuticals International Private Limited the #1 Indian exporter?

BDR Pharmaceuticals International Private Limited is the #1 Indian exporter in 2 products: Thalidomide (24.2% market share), Olaparib (31.0% market share).

What therapeutic categories does BDR Pharmaceuticals International Private Limited cover?

BDR Pharmaceuticals International Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (76.1%, 10 products), Immunosuppressants (17.1%, 1 products), Antifungals (6.8%, 1 products).

Get Full BDR Pharmaceuticals International Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.